With the full results of the Thai HIV vaccine trial released this morning (October 20) at a conference in Paris, the HIV/AIDS research community can breathe a sigh of relief: The vaccine candidate does appear to offer a real, albeit modest, level of protection against HIV infection.
Human Immunodeficiency Virus
Image: Wikimedia commons,
"What we saw today was a more complete presentation of different types of analyses that were done, [and] the scientific conclusions are as they were described earlier," said virologist linkurl:Gary Nabel,;http://www3.niaid.nih.gov/labs/aboutlabs/VRC/virologyAndVectorCoreLaboratories/ director of the Vaccine Research Center (VRC) at the National Institute of Allergy and Infectious Diseases in Bethesda, Md., who did not participate in the research. "This really is a landmark study for HIV vaccine research." After the linkurl:preliminary results were released;http://www.the-scientist.com/blog/display/55995/ late last month, linkurl:many raised concerns;http://www.the-scientist.com/blog/display/56052/ about whether the 31% decrease in HIV infection risk shown by the vaccine candidate was genuine or...
New England Journal of Medicine (NEJM)NEJM

Interested in reading more?

Become a Member of

Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member?